NASDAQ:PODD - Nasdaq - US45784P1012 - Common Stock - Currency: USD
316.67
+6 (+1.93%)
The current stock price of PODD is 316.67 USD. In the past month the price increased by 24.68%. In the past year, price increased by 69.1%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABT | ABBOTT LABORATORIES | 27.61 | 228.91B | ||
ISRG | INTUITIVE SURGICAL INC | 73.49 | 201.23B | ||
BSX | BOSTON SCIENTIFIC CORP | 38.1 | 152.15B | ||
SYK | STRYKER CORP | 30.97 | 148.13B | ||
MDT | MEDTRONIC PLC | 16.07 | 110.05B | ||
BDX | BECTON DICKINSON AND CO | 12.44 | 50.35B | ||
EW | EDWARDS LIFESCIENCES CORP | 28.77 | 43.97B | ||
IDXX | IDEXX LABORATORIES INC | 44.7 | 41.29B | ||
RMD | RESMED INC | 27.28 | 36.31B | ||
GEHC | GE HEALTHCARE TECHNOLOGY | 16.11 | 33.93B | ||
DXCM | DEXCOM INC | 51.55 | 33.35B | ||
PHG | KONINKLIJKE PHILIPS NVR- NY | 16.58 | 23.54B |
Insulet Corp. is a medical device company, which engages in the development, manufacture, and marketing of an insulin infusion system for people with insulin-dependent diabetes. The company is headquartered in Acton, Massachusetts and currently employs 3,900 full-time employees. The company went IPO on 2007-05-15. The company is primarily engaged in the development, manufacture and sale of its continuous insulin delivery systems for people with insulin-dependent diabetes. The Omnipod System includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5), the Omnipod DASH Insulin Management System, the Omnipod Insulin Management System, and Omnipod GO. The company also produces pods for Amgen for use in the Neulasta Onpro kit, a delivery system for Amgen's Neulasta. The Omnipod platform offers continuous insulin delivery that provides various benefits of insulin pump therapy in a way without the need for external tubing required with conventional pumps. The small, lightweight, self-adhesive disposable tubeless Omnipod device (Pod), can be worn in multiple locations, including the abdomen, hip, back of upper arm, upper thigh, or lower back, and delivers insulin into the body through a small flexible tube. Omnipod 5 includes an AID algorithm embedded in the Pod.
INSULET CORP
100 Nagog Park
Acton MASSACHUSETTS 01720 US
CEO: Shacey Petrovic
Employees: 3900
Phone: 19786007000
The current stock price of PODD is 316.67 USD. The price increased by 1.93% in the last trading session.
The exchange symbol of INSULET CORP is PODD and it is listed on the Nasdaq exchange.
PODD stock is listed on the Nasdaq exchange.
31 analysts have analysed PODD and the average price target is 323.11 USD. This implies a price increase of 2.03% is expected in the next year compared to the current price of 316.67. Check the INSULET CORP stock analysts ratings, price target forecast and up-and down grades for more detailed information.
INSULET CORP (PODD) has a market capitalization of 22.28B USD. This makes PODD a Large Cap stock.
INSULET CORP (PODD) currently has 3900 employees.
INSULET CORP (PODD) has a support level at 260.47. Check the full technical report for a detailed analysis of PODD support and resistance levels.
The Revenue of INSULET CORP (PODD) is expected to grow by 19.17% in the next year. Check the estimates tab for more information on the PODD EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
PODD does not pay a dividend.
INSULET CORP (PODD) will report earnings on 2025-08-06, after the market close.
The PE ratio for INSULET CORP (PODD) is 87.48. This is based on the reported non-GAAP earnings per share of 3.62 and the current share price of 316.67 USD. Check the full fundamental report for a full analysis of the valuation metrics for PODD.
The outstanding short interest for INSULET CORP (PODD) is 3.18% of its float. Check the ownership tab for more information on the PODD short interest.
ChartMill assigns a technical rating of 10 / 10 to PODD. When comparing the yearly performance of all stocks, PODD is one of the better performing stocks in the market, outperforming 95.76% of all stocks.
ChartMill assigns a fundamental rating of 7 / 10 to PODD. Both the health and profitability get an excellent rating, making PODD a very profitable company, without any liquidiy or solvency issues.
Over the last trailing twelve months PODD reported a non-GAAP Earnings per Share(EPS) of 3.62. The EPS increased by 12.42% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | 20.19% | ||
ROA | 13.55% | ||
ROE | 34.52% | ||
Debt/Equity | 1.08 |
ChartMill assigns a Buy % Consensus number of 83% to PODD. The Buy consensus is the average rating of analysts ratings from 31 analysts.
For the next year, analysts expect an EPS growth of 29.11% and a revenue growth 19.17% for PODD